The 24th Annual Diabetes Technology Meeting (DTM), held from October 15-17, 2024, was a significant milestone for Orange Biomed. This gathering of global experts, innovators and healthcare providers focused on cutting-edge technologies shaping the future of diabetes care. For us, the event was a remarkable opportunity to present our OBM rapid A1C testing device and engage with industry thought leaders. As we reflect on our experience at DTM, we’re excited to share key insights, lessons learned and the direction we are taking toward revolutionizing diabetes care.

Day 1: Unveiling Smart Systems and AI in Diabetes Management

The first day set the tone with discussions on AI-driven solutions and remote patient monitoring. These conversations confirmed that technology will continue to play a transformative role in improving diabetes care.

  • Mark Clements from Kansas City Children’s Mercy Hospital explained how a data aggregation dashboard, developed with Stanford, enables clinicians to track CGM data and forecast potential health issues before they escalate. His work aligns with our goal of making real-time monitoring more accessible to both patients and providers.
  • Ali Cinar from the Illinois Institute of Technology provided critical insights into AI’s evolving role in healthcare. The challenges he outlined—like ethical concerns and scalability—resonate with our journey as we explore advanced algorithms to ensure the precision of our A1C testing.
  • We introduced our A1C testing solution to Jeremy Alkire of Close Concerns and discussed potential applications in clinical settings. Kelly Close also shared valuable insights with us.
  • Our conversations with many diabetes industry leaders provided valuable insights into feasibility trials, setting the stage for potential further collaboration in the future.

Day 2: Integrating Real-World Evidence into Clinical Research

The second day revolved around the integration of Real-World Data (RWD) into clinical research, highlighting how Real-World Evidence (RWE) can complement traditional clinical trials.

  • Julia Mader shared practical examples of multi-stakeholder collaborations that leverage RWD (real-world data) to improve patient outcomes. Her insights align with our process of using real-world insights in product development.
  • During our conversation about using microfluidics, we explored potential partnerships with Integrated Medical Sensors and engaged with Muhammad Mujeeb-U-Rahman on opportunities for Korean manufacturing and US-based SBIR funding. These connections could be instrumental in streamlining production and reducing costs.
  • Dr. Tim Bailey provided critical insights into navigating the FDA clearance process, helping us fine-tune our roadmap toward regulatory approval.
  • At our booth, we caught the attention of a market research professional from a leading healthcare technology company, who described our device as “cool,” and on their radar, reinforcing its market relevance.

Day 3: A Patient-Centered Approach and Future Collaborations

On the final day, discussions focused on the importance of aligning new technologies with patient needs.

  • Dr. Anthony Maiorana from the FDA highlighted the need for medical devices to integrate both patient-friendly design and regulatory compliance. His talk underscored the importance of usability, validating the design decisions we’ve made for our A1C device.
  • Our presentation at the Startup Showcase was met with enthusiasm, as attendees praised our device’s portability, durability and long shelf life. These features make our technology especially relevant for use in diverse settings without the need for refrigeration.
  • Kelly Close provided critical feedback on refining our statistical algorithms to ensure precision across ethnicities and patient demographics. Her insights will guide us as we continue to enhance the performance of our A1C testing device.
  • Conversations with Amazon representatives Varun Pant and Andreas Caduff started a dialogue about potential data transfer solutions, as they and others at the conference reinforced the role of digital connectivity in modern healthcare.

Innovations Announced at the Diabetes Technology Meeting 2024

We unveiled several key enhancements to our OBM rapid A1C technology during the event:

  • Improved Accuracy : The integration of advanced algorithms ensures more reliable A1C measurements, even across diverse patient populations.
  • User-Friendly Interface : A redesigned interface makes it easier for patients and providers to operate the device and interpret results.
  • Extended Shelf Life : The improved shelf life of our device ensures better inventory management and accessibility for patients and clinics.

Health Equity in Diabetes Care: Our Commitment

The theme of health equity was central to many discussions at the Diabetes Technology Meeting in 2024. Barriers to quality care disproportionately affect certain communities, contributing to worse health outcomes. At Orange Biomed, we are committed to making diabetes care more inclusive and accessible.

  • Affordable Pricing : We aim to keep our products competitively priced to ensure that more people can access reliable testing.
  • Community Outreach Programs : We are developing partnerships with local organizations to extend access to our technology in underserved communities.
  • Educational Resources : We will provide training programs for both patients and healthcare providers to promote the effective use of our A1C device.

Strengthening Partnerships and Exploring New Collaborations

The relationships we built at DTM will play a pivotal role in our growth. Collaborations with companies like Amazon, Abbott and Medtronic align with our mission to deliver seamless healthcare solutions through technology integration.

  • Joint Research Initiatives : We are exploring collaborative research opportunities that will further validate our technology and expand its applications.
  • Technology Integration Projects : We aim to integrate our solutions with existing healthcare infrastructure, ensuring that patient data is easily accessible to healthcare providers.

Future Initiatives and Strategic Roadmap

The insights gained at DTM will inform our strategic initiatives moving forward:

  • Research and Development : We are investing in new features that will complement our current offerings and address unmet needs in diabetes care.
  • Expanded Product Line : Based on feedback from the event, we plan to develop additional tools that support comprehensive diabetes management.
  • User Engagement Programs : Our upcoming initiatives will involve patients and providers in the product development process, ensuring that our solutions align with real-world needs.

Our long-term vision is to become a leader in diabetes technology, committed to continuous innovation and a patient-first approach. With the momentum from DTM 2024, we are poised to transform diabetes care and make a lasting impact.

A Transformative Experience for Orange Biomed

The Diabetes Technology Meeting 2024 was a defining moment for Orange Biomed, reinforcing our belief that collaboration and innovation are essential to driving meaningful change. The event provided a platform to showcase our technology, receive invaluable feedback and build strategic relationships that will guide our future initiatives.

We are excited to implement the insights gained at DTM and continue our journey toward delivering next-generation A1C testing solutions. With these partnerships and innovations, we are confident that Orange Biomed will play a pivotal role in shaping the future of diabetes care.

Learn More and Join Us on This Journey

To explore our latest innovations and discover how we are addressing the challenges in diabetes care, visit our DTM event page. If you are interested in partnering with us, we welcome you to connect and explore collaborative opportunities that will drive positive change in the healthcare industry.

,